CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

The trade war between China and the US is entering the next round and reaching a new peak. The Middle Kingdom is restricting ...

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double ...

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Pfizer raised its full-year profit forecast on Tuesday after topping Wall Street expectations for second-quarter results as ...

Now, it’s worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...